Detection of human immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on highly active antiretroviral therapy.
We evaluated the shedding of human immunodeficiency virus (HIV)-1 particles into continuous ambulatory peritoneal dialysis (CAPD) effluents of HIV-positive patients with end-stage renal disease (ESRD).



A total of 58 HIV-positive patients with ESRD on highly active antiretroviral therapy (HAART) who had Tenckhoff catheters inserted between September 2012 and February 2015 were prospectively reviewed and followed for 18 months. Peritoneal dialysis (PD) effluent samples from functioning CAPD catheters and plasma samples were obtained at three points during regular clinic visits on days 45 ± 37, 200 ± 19 and 377 ± 13 after catheter insertion. All specimens were stored at -20°C, and each batch was analysed by Roche quantitative HIV-1 polymerase chain reaction assay to detect HIV-1 particles. Clustered logistic regression was used to test for independent predictors of HIV-1 detection in CAPD effluents.



HIV-1 RNA above 20 copies/mL assay limit was detectable in 19% (first batch), 26.3% (second batch) and 20% (third batch) of PD effluent specimens. HIV-1 RNA was detectable in PD fluid, without corresponding detection in the paired plasma in 3.4% (first batch), 5.3% (second batch) and 10% (third batch) of samples. Detection of HIV-1 in plasma sample (odds ratios 3.94; 95% confidence interval 1.14-13.55; P = 0.030), body mass index, serum albumin and HAART regimen were found to be significantly associated with HIV-1 detection in PD effluents.



HIV particles are shed in detectable amounts into CAPD effluents even in patients with suppressed plasma viral load, raising concerns of a localized sanctuary site and potential infectivity of HIV-positive CAPD patients on a full complement of HAART.
Inkosi Albert Luthuli Central Hospital, Durban, South Africa.|Department of Nephrology, University of KwaZulu-Natal, Durban, South Africa.
Kwazi C Z
KC
Ndlovu
School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
Wilbert
W
Sibanda
Inkosi Albert Luthuli Central Hospital, Durban, South Africa.|Department of Nephrology, University of KwaZulu-Natal, Durban, South Africa.
Alain
A
Assounga
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism*; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis / Q000235:genetics*; D019562:Viral Load / Q000187:drug effects; D017201:Virus Shedding / Q000187:drug effects*
D012367:RNA, Viral
HAART; HIV-1 RNA; PD effluents; continuous ambulatory peritoneal dialysis; viral load